Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknow...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:JAMA Dermatol
المؤلفون الرئيسيون: Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Boguniewicz, Mark, Sher, Lawrence, Gooderham, Melinda J., Beck, Lisa A., Guttman-Yassky, Emma, Pariser, David, Blauvelt, Andrew, Weisman, Jamie, Lockshin, Benjamin, Hultsch, Thomas, Zhang, Qin, Kamal, Mohamed A., Davis, John D., Akinlade, Bolanle, Staudinger, Heribert, Hamilton, Jennifer D., Graham, Neil M. H., Pirozzi, Gianluca, Gadkari, Abhijit, Eckert, Laurent, Stahl, Neil, Yancopoulos, George D., Ruddy, Marcella, Bansal, Ashish
التنسيق: Artigo
اللغة:Inglês
منشور في: American Medical Association 2019
الموضوعات:
Original Investigation
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865265/
https://ncbi.nlm.nih.gov/pubmed/31693077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.3336
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة